![]() ![]() ConclusionĬompared with endocrine therapy alone, the addition of chemotherapy did not improve the prognosis of patients with luminal type A and lymph node positive cancer instead, side effects of the additional chemotherapy may have negatively affected prognosis. Tumor size, vascular invasion, and age did not show significant correlations with breast cancer prognosis. The hazard ratio of relapse-free survival to disease-free survival was 1.30 (95% CI 0.85, 1.77). The hazard ratio of overall survival for lymph node-positive, luminal A breast cancer patients who received chemotherapy and endocrine therapy was 1.86 and 95% CI 1.26, 2.81. The hazard ratio of overall survival of luminal A breast cancer patients who received both chemotherapy and endocrine therapy was 1.73 (95% CI 1.23, 2.43). Article quality was evaluated by sensitivity analysis, and Begg’s and Egger’s tests were used to measure publication bias. On the basis of a test for heterogeneity, we selected the random effects model or fixed effects model for meta-analysis. ![]() To assess the association between chemotherapy and prognosis of patients with breast cancer of luminal A subtype and lymph node-positive, luminal A subtype breast cancer MethodsĪrticles published between January 1, 2010, and May 1, 2020, were collected from PubMed, Embase, and Web of Science databases. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |